Cipla Ltd
NSE:CIPLA

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
NSE:CIPLA
Watchlist
Price: 1 475.75 INR 0.39% Market Closed
Market Cap: 1.2T INR
Have any thoughts about
Cipla Ltd?
Write Note

Cipla Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cipla Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Cipla Ltd
NSE:CIPLA
Income from Continuing Operations
â‚ą44.9B
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
14%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Income from Continuing Operations
â‚ą54.3B
CAGR 3-Years
40%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Income from Continuing Operations
â‚ą111.4B
CAGR 3-Years
21%
CAGR 5-Years
18%
CAGR 10-Years
5%
Lupin Ltd
NSE:LUPIN
Income from Continuing Operations
â‚ą26.5B
CAGR 3-Years
N/A
CAGR 5-Years
71%
CAGR 10-Years
1%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Income from Continuing Operations
â‚ą18B
CAGR 3-Years
12%
CAGR 5-Years
27%
CAGR 10-Years
8%
M
Mankind Pharma Ltd
NSE:MANKIND
Income from Continuing Operations
â‚ą19.4B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cipla Ltd
Glance View

Market Cap
1.2T INR
Industry
Pharmaceuticals
Economic Moat
Narrow

In the bustling heart of India's pharmaceutical landscape, Cipla Ltd. stands as a venerable name, tracing its roots back to 1935. Founded by Khwaja Abdul Hamied, Cipla embarked on a journey fueled by the vision of making healthcare accessible and affordable to the masses. Over decades, the company has morphed into a global pharmaceutical powerhouse, seamlessly integrating science and compassion. Cipla primarily operates through the production and sale of active pharmaceutical ingredients (APIs) and a wide array of generic medicines, catering to various therapeutic segments such as respiratory, anti-retroviral, urology, cardiology, and oncology. The company’s manufacturing prowess is underpinned by its state-of-the-art facilities, strategically located to serve markets across the globe, ensuring its competitive edge in quality and cost-efficiency. Cipla's revenue streams elegantly dance around its core philosophy—offering affordable medication without compromising quality. The company capitalizes on its robust R&D capabilities to develop and market generics that serve as cost-effective alternatives to patented medicines. Its business model thrives on the volume-driven sale of these generics, both in domestic and international markets. Additionally, Cipla reinforces its revenue through strategic partnerships and collaborations across the pharmaceutical value chain, and by out-licensing its products in various regions. By continually expanding its pipeline to include biosimilars and new drug delivery systems, Cipla not only strengthens its foothold in existing markets but also pioneers growth into new pharmaceutical frontiers.

CIPLA Intrinsic Value
1 165.02 INR
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Cipla Ltd's Income from Continuing Operations?
Income from Continuing Operations
44.9B INR

Based on the financial report for Sep 30, 2024, Cipla Ltd's Income from Continuing Operations amounts to 44.9B INR.

What is Cipla Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
14%

Over the last year, the Income from Continuing Operations growth was 29%. The average annual Income from Continuing Operations growth rates for Cipla Ltd have been 20% over the past three years , 22% over the past five years , and 14% over the past ten years .

Back to Top